A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Study summary

This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAtezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Recurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 19, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?19 U.S. locations

Locations may change over time.

Who runs it?Genentech, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Genentech, Inc.
Interventions being studied: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→Recurrent or relapsed→

Treatment approach

Immunotherapy→Surgery→

Study topics

Before surgery (neoadjuvant)→After surgery (adjuvant)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
Adequate pulmonary and cardiac function
Available biopsy of primary tumor with adequate samples
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Reasons someone may not be able to joinExclusion criteria

NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
Any prior therapy for lung cancer within 3 years.
Prior treatment with anti-PD-1 or PD-L1 therapies
History or risk of autoimmune disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

City of Hope Comprehensive Cancer CenterDuarte, California
UCLA Cancer CenterSanta Monica, California
University Of ColoradoAurora, Colorado
Yale Cancer CenterNew Haven, Connecticut
Moffitt Cancer CenterTampa, Florida
Emory University; Winship Cancer InstituteAtlanta, Georgia
Dana Farber Cancer Institute; Brigham and Womens HospitalBoston, Massachusetts
Mass General/North Shore CancerDanvers, Massachusetts
Karmanos Cancer Inst; Hematology/OncologyDetroit, Michigan
Washington University; Wash Uni. Sch. Of MedSt Louis, Missouri
Dartmouth Hitchcock Medical CenterLebanon, New Hampshire
Memorial Sloan Kettering - MonmouthMiddletown, New Jersey

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 19, 2024. Always confirm current availability with the study team.

View original record ↗